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ABSTRACT A small percentage of HIV-infected subjects (2 to 15%) are able to control disease progression for many years without
antiretroviral therapy. Years of intense studies of virologic and immunologic mechanisms of disease control in such individuals
yielded a number of possible host genes that could be responsible for the preservation of immune functions, from immune surveillance genes, chemokines, or their receptors to anti-HIV restriction factors. A recent mBio paper by Rappocciolo et al. (G.
Rappocciolo, M. Jais, P. Piazza, T. A. Reinhart, S. J. Berendam, L. Garcia-Exposito, P. Gupta, and C. R. Rinaldo, mBio 5:e0103113, 2014) describes another potential factor controlling disease progression: cholesterol levels in antigen-presenting cells. In this
commentary, we provide a brief background of the role of cholesterol in HIV infection, discuss the results of the study by Rappocciolo et al., and present the implications of their findings.

U

nderstanding the genetic basis of natural resistance to HIV-1
is a major goal in the effort to control HIV. Previous studies
to identify and delineate host genetic variants responsible for
complete or partial resistance to HIV infection or disease progression have pointed to host genes involved in the HIV-1 replication
cycle (CCR5, CCR2b, chemokines), immune surveillance (major
histocompatibility complex class I) or restriction factors (members of the apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like, family; tripartite motif-containing protein 5␣;
and tetherin) (recently reviewed in reference 1). Such studies are
valuable, as they provide important clues to identifying the viral
and host targets for developing more efficacious therapies. The
recent report in mBio by Rappocciolo et al. (2) throws new light on
a molecule whose role in aiding and abetting HIV replication is
already known— cholesterol. That study shows that the level of
cholesterol in immune cells may be a determinant of HIV spread
within the body. While the underlying genetic basis of this is still
unknown, the study provides some important hints.
Cholesterol has been shown to be required for the entry or
fusion of many different viruses (3–5), and the list continues to
expand (6). The role of cholesterol in HIV replication has been
studied for over 10 years. Early reports demonstrated that cholesterol depletion from virus-producing cells suppresses virus production (7), whereas depletion of cholesterol from mature virions
or target cells inhibits virus-cell fusion and infection (8–11). This
dependence of HIV on host cell cholesterol was related to viral
assembly on cholesterol-rich lipid rafts of the plasma membrane
and the role of cholesterol and lipid rafts in membrane fluidity (7,
12, 13). Thus, reports that HIV actively controls the cholesterol
metabolism of the host cell came as little surprise. HIV, via its
protein Nef, stimulates cholesterol uptake and biosynthesis by activating the transcription of sterol-responsive element binding
factor 2 (SREBF-2) and SREBF-2-regulated genes (14), and Nef
also inhibits the activity of the cellular cholesterol transporter
ATP-binding cassette A1 (ABCA1), thus reducing cholesterol efflux from cells (15). In addition, Nef binds cholesterol and delivers
it to lipid rafts (16). Together, these effects lead to an increase in
intracellular cholesterol, an increase in lipid raft abundance, and
an increase in viral production and infectivity (17). Conversely,
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depletion of cellular cholesterol by ABCA1 activation potently inhibits HIV replication (18–20).
The paper by Rappocciolo and colleagues describes another
role that cholesterol plays in HIV infection (2). Investigating the
mechanistic basis underlying the ability of a small group of HIVinfected persons to control HIV infection for many years without
antiretroviral treatment, the authors compared antigenpresenting cells (APCs) from nonprogressors (NPs) and progressors (PRs) for the ability to trans infect susceptible CD4⫹ T cells.
Trans infection is the process by which APCs such as dendritic
cells (DCs) or certain B cells can take up HIV-1 and participate in
enabling the infection of CD4⫹ T cells (21). It is different from the
standard cell-to-cell infection (cis infection) in that the APCs are
not productively infected by HIV, so the virus they transduce to
target cells is the virus they have captured and preserved. However, trans infection is similar to cis infection in that the target cells
must express CD4 and coreceptor and the formation of a virological synapse is involved. Previous study by Viglianti’s group demonstrated that trans infection by DCs depends on cholesterol levels
and can be suppressed or stimulated by manipulating cellular cholesterol content via stimulation of the nuclear receptors LXR and
PPAR␥ or the targeted knockdown of ABCA1, respectively (22).
Rappocciolo et al. found that APCs (DCs and B cells) from NPs,
when pulsed with HIV in vitro, did not trans infect autologous or
heterologous CD4⫹ T cells, whereas cells from PRs efficiently
transferred the virus to susceptible cells. Importantly, the defect
was localized to APCs, as T cells from both NPs and PRs were
equally efficiently infected by cell-free virus.
In the authors’ search for a mechanistic basis for this finding,
they made a startling observation—the ability of APCs to trans
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FIG 1 Schematic depicting the role of ABCA1 expression levels in APCs during HIV-1 trans infection. Individuals with genetically determined high levels of
ABCA1 gene expression have lower cholesterol levels than normal subjects in cells expressing ABCA1, such as DCs, whereas the cholesterol levels in cells where
ABCA1 is not expressed, such as T cells, are similar in these two groups. The paper by Rappocciolo et al. suggests that HIV disease in individuals with high ABCA1
expression progresses more slowly than in normal individuals. They demonstrate an absence of trans infection of CD4⫹ T cells by DCs and B cells derived from
NPs (individuals with high ABCA1 expression levels). Cholesterol depletion has been shown to inhibit HIV uptake by DCs. Therefore, high ABCA1 expression
is expected to reduce HIV uptake and consequently trans infection. Trans infection proceeds through a virological synapse, which is formed with the participation
of lipid rafts. Lipid rafts are reduced when ABCA1 expression increases. See text for details.

infect CD4⫹ T cells was directly correlated with APC cholesterol
content. In other words, cells from NPs had lower cholesterol than
cells from PRs. Replenishment of cholesterol in APCs from NPs
reversed the block to trans infection, and depletion of cholesterol
or inhibition of cholesterol biosynthesis with statins blocked the
ability of APCs from PRs to transfer HIV to susceptible cells. Of
note, the difference in APC cholesterol content between PRs and
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NPs is likely due, at least in part, to genetic or epigenetic regulation, as ABCA1 expression was higher in cells from NPs. These
findings support a previously proposed role for ABCA1 as an innate anti-HIV-1 (and probably a more general antiviral) factor
(17). In this case, the decreased cholesterol levels controlled by
ABCA1 affect the ability of DCs and B cells to capture HIV and
transfer it to susceptible cells in a process that requires tight cell-
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to-cell contact to form a virological synapse (Fig. 1). Jolly and
Sattentau previously showed that the formation of virological synapses between HIV-infected and uninfected T cells requires the
integrity of lipid rafts (23). It is likely that these are the same
membrane structures as those involved in the assembly of infectious HIV-1 particles. Thus, the mechanism of anti-HIV-1 activity
of ABCA1 may be the same in all cells and comes down to reduction of lipid raft abundance. The authors examined the ability of B
cells, isolated from PRs and NPs both before and after seroconversion, to participate in trans infection and found that the inability to trans infect existed prior to seroconversion, thus suggesting
that the inability of APC to trans infect is an innate property of
NPs. The specific genetic or epigenetic mechanisms underlying
the high ABCA1 expression in APCs from nonprogressors remain
to be uncovered. It is not unlikely that this is due to single nucleotide polymorphism in ABCA1 or genes encoding transcription
factors that specifically regulate ABCA1 expression in APCs.
Results of this study, while provocative and exciting, are only
the first step in understanding the mechanisms that operate in the
ability of some individuals to control HIV replication. It is most
likely that several mechanisms that engage different molecular
players are involved, and careful studies are needed to pinpoint
the contribution of cholesterol to each mechanism. It will be important to determine whether cholesterol levels of APCs can explain the differences between elite controllers (undetectable viral
loads), viremic controllers (plasma HIV-1 levels of 50 to 2,000
copies/ml), and viremic nonprogressors (variable viral loads but
stable CD4⫹ T cell counts). Although the sample size in the study
by Rappocciolo et al. was small (n ⫽ 8), it is striking that the APCs
from all 8 NP individuals were unable to effect trans infection.
Some questions remain unanswered. The authors demonstrated the dependence of trans infection on cholesterol by repleting APCs with cholesterol prior to infection. However, since repletion was performed prior to loading of the APCs with HIV, it is
unclear if cholesterol is required for the process of HIV-1 capture
by APCs, for the actual trans infection process, or for both. Trans
infection of CD4⫹ T cells by APCs, in particular DCs, is known to
play a significant role in the mucosal transmission of HIV (24),
but its contribution to the posttransmission stage of disease progression remains unknown. It is possible that B cells play a role at
this step (25), but evidence for this remains scarce. It is also intriguing that the cholesterol levels in the recipient CD4⫹ T cells
did not matter; rather, the cholesterol levels in the APCs controlled trans infection. This conclusion was based on experiments
where the authors used 20% serum to culture T cells; given low
ABCA1 expression in T cells, such culture conditions could overload the cells with cholesterol, masking differences between cells
from PRs and those from NPs. High ABCA1 expression in nonprogressors may also be responsible for the restricted infection of
macrophages and other myeloid cells that are productively infected with HIV. This may limit the viral reservoir (26), contributing to nonprogression. In any case, the possibility that levels of
ABCA1 expression may determine the control of HIV infection
deserves further study. The implications and translational opportunities are colossal, from preexposure prophylaxis to microbicides to clinical maintenance of HIV-infected subjects.
ACKNOWLEDGMENTS
This work was supported by NIH grants R01 HL093818 and R01
HL101274 to M.I.B. and R37 AI030861 to V.R.P., by the District of Co-

May/June 2014 Volume 5 Issue 3 e01396-14

lumbia Developmental Center for AIDS Research (DC D-CFAR) (P30
AI087714), and by Einstein-Montefiore CFAR (P30 AI051519).
We thank Kartik Chandran for critical reading of the manuscript.

REFERENCES
1. Walker BD, Yu XG. 2013. Unravelling the mechanisms of durable control
of HIV-1. Nat. Rev. Immunol. 13:487– 498. http://dx.doi.org/10.1038/
nri3478.
2. Rappocciolo G, Jais M, Piazza P, Reinhart TA, Berendam SJ, GarciaExposito L, Gupta P, Rinaldo CR. 2014. Alterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors. mBio 5(3):
e01031-13. http://dx.doi.org/10.1128/mBio.01031-13.
3. Daya M, Cervin M, Anderson R. 1988. Cholesterol enhances mouse
hepatitis virus-mediated cell fusion. Virology 163:276 –283. http://
dx.doi.org/10.1016/0042-6822(88)90267-X.
4. Vashishtha M, Phalen T, Marquardt MT, Ryu JS, Ng AC, Kielian M.
1998. A single point mutation controls the cholesterol dependence of
Semliki Forest virus entry and exit. J. Cell Biol. 140:91–99. http://
dx.doi.org/10.1083/jcb.140.1.91.
5. Danthi P, Chow M. 2004. Cholesterol removal by methyl-betacyclodextrin inhibits poliovirus entry. J. Virol. 78:33– 41. http://
dx.doi.org/10.1128/JVI.78.1.33-41.2004.
6. Petersen J, Drake MJ, Bruce EA, Riblett AM, Didigu CA, Wilen CB,
Malani N, Male F, Lee FH, Bushman FD, Cherry S, Doms RW, Bates P,
Briley K, Jr.. 2014. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog. 10(2):e1003911. http://
dx.doi.org/10.1371/journal.ppat.1003911.
7. Ono A, Freed EO. 2001. Plasma membrane rafts play a critical role in
HIV-1 assembly and release. Proc. Natl. Acad. Sci. U. S. A. 98:
13925–13930. http://dx.doi.org/10.1073/pnas.241320298.
8. Mañes S, del Real G, Lacalle RA, Lucas P, Gómez-Moutón C, SánchezPalomino S, Delgado R, Alcamí J, Mira E, Martinez AC. 2000. Membrane raft microdomains mediate lateral assemblies required for HIV-1
infection. EMBO Rep. 1:190 –196. http://dx.doi.org/10.1093/embo
-reports/kvd025.
9. Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D. 2002. Role for
human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J. Virol. 76:10356 –10364. http://dx.doi.org/10.1128/
JVI.76.20.10356-10364.2002.
10. Viard M, Parolini I, Sargiacomo M, Fecchi K, Ramoni C, Ablan S,
Ruscetti FW, Wang JM, Blumenthal R. 2002. Role of cholesterol in
human immunodeficiency virus type 1 envelope protein-mediated fusion
with host cells. J. Virol. 76:11584 –11595. http://dx.doi.org/10.1128/
JVI.76.22.11584-11595.2002.
11. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. 2001.
Lipid rafts and HIV pathogenesis: host membrane cholesterol is required
for infection by HIV type 1. AIDS Res. Hum. Retroviruses 17:1009 –1019.
http://dx.doi.org/10.1089/088922201300343690.
12. Nguyen DH, Hildreth JE. 2000. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane
lipid rafts. J. Virol. 74:3264 –3272. http://dx.doi.org/10.1128/
JVI.74.7.3264-3272.2000.
13. Blanchette CD, Lin WC, Ratto TV, Longo ML. 2006. Galactosylceramide domain microstructure: impact of cholesterol and nucleation/
growth conditions. Biophys. J. 90:4466 – 4478. http://dx.doi.org/10.1529/
biophysj.105.072744.
14. van ’t Wout AB, Swain JV, Schindler M, Rao U, Pathmajeyan MS,
Mullins JI, Kirchhoff F. 2005. Nef induces multiple genes involved in
cholesterol synthesis and uptake in human immunodeficiency virus type
1-infected T cells. J. Virol. 79:10053–10058. http://dx.doi.org/10.1128/
JVI.79.15.10053-10058.2005.
15. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L,
Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Sviridov D. 2006. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 4(11):e365.
http://dx.doi.org/10.1371/journal.pbio.0040365.
16. Zheng YH, Plemenitas A, Fielding CJ, Peterlin BM. 2003. Nef increases
the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc. Natl. Acad. Sci. U. S. A. 100:8460 – 8465. http://
dx.doi.org/10.1073/pnas.1437453100.
17. Cui HL, Grant A, Mukhamedova N, Pushkarsky T, Jennelle L,
Dubrovsky L, Gaus K, Fitzgerald ML, Sviridov D, Bukrinsky M. 2012.

®

mbio.asm.org 3

Downloaded from mbio.asm.org on June 17, 2014 - Published by mbio.asm.org

Commentary

HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that
competes with ABCA1-dependent cholesterol efflux. J. Lipid Res. 53:
696 –708. http://dx.doi.org/10.1194/jlr.M023119.
18. Morrow MP, Grant A, Mujawar Z, Dubrovsky L, Pushkarsky T, Kiselyeva Y, Jennelle L, Mukhamedova N, Remaley AT, Kashanchi F,
Sviridov D, Bukrinsky M. 2010. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette
transporter A1. Mol. Pharmacol. 78:215–225. http://dx.doi.org/10.1124/
mol.110.065029.
19. Dubrovsky L, Van Duyne R, Senina S, Guendel I, Pushkarsky T,
Sviridov D, Kashanchi F, Bukrinsky M. 2012. Liver X receptor agonist
inhibits HIV-1 replication and prevents HIV-induced reduction of plasma
HDL in humanized mouse model of HIV infection. Biochem. Biophys.
Res. Commun. 419:95–98. http://dx.doi.org/10.1016/j.bbrc.2012.01.137.
20. Jiang H, Badralmaa Y, Yang J, Lempicki R, Hazen A, Natarajan V. 2012.
Retinoic acid and liver X receptor agonist synergistically inhibit HIV infection in CD4⫹ T cells by up-regulating ABCA1-mediated cholesterol
efflux. Lipids Health Dis. 11:69. http://dx.doi.org/10.1186/1476-511X-11
-69.

21. Rinaldo CR. 2013. HIV-1 trans infection of CD4(⫹) T cells by professional antigen presenting cells. Scientifica (Cairo) 2013:164203. http://
dx.doi.org/10.1155/2013/164203.
22. Hanley TM, Blay Puryear W, Gummuluru S, Viglianti GA. 2010.
PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1
capture and trans-infection. PLoS Pathog. 6:e1000981. http://dx.doi.org/
10.1371/journal.ppat.1000981.
23. Jolly C, Sattentau QJ. 2005. Human immunodeficiency virus type 1
virological synapse formation in T cells requires lipid raft integrity. J.
Virol. 79:12088 –12094. http://dx.doi.org/10.1128/JVI.79.18.12088
-12094.2005.
24. McDonald D. 2010. Dendritic cells and HIV-1 trans-infection. Viruses
2:1704 –1717. http://dx.doi.org/10.3390/v2081704.
25. Rappocciolo G, Piazza P, Fuller CL, Reinhart TA, Watkins SC, Rowe
DT, Jais M, Gupta P, Rinaldo CR. 2006. DC-SIGN on B lymphocytes is
required for transmission of HIV-1 to T lymphocytes. PLoS Pathog. 2(7):
e70. http://dx.doi.org/10.1371/journal.ppat.0020070.
26. Kumar A, Abbas W, Herbein G. 2014. HIV-1 latency in monocytes/
macrophages. Viruses 6:1837–1860. http://dx.doi.org/10.3390/v6041837.

The views expressed in this Commentary do not necessarily reflect the views of this journal or of ASM.

4

®

mbio.asm.org

May/June 2014 Volume 5 Issue 3 e01396-14

Downloaded from mbio.asm.org on June 17, 2014 - Published by mbio.asm.org

Commentary

